Comparing the current results to its competitors, Modular Medical Inc reported Revenue decrease in the 1 quarter 2026 year on year by 0 %, slower than the combined decrease of the MODD's competitors by -7.93 %, recorded in the same quarter.
Modular Medical Inc, slower than the average decrease reported by the company's competitors of -62.33 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -62.33 %
Modular Medical Inc's Comment on Competition and Industry Peers
The company projects that its Pivot pump will have a cost of goods approximately 50% lower than its nearest patch pump competitor. The Pivot pump is smaller in volume than Insulet's Omnipod and contains a 3 mL insulin reservoir, compared to the Omnipod's 2 mL reservoir. This volume difference is notable for patients requiring more than 2 mL of insulin. The company focuses on European and select international markets, emphasizing a lower-cost patch pump design and reduced training requirements. In the U.S. insulin pump market in 2026, five companies commercialize pumps, with Insulet, Tandem, and Minimed holding significant market shares of 43%, 34%, and 21%, respectively. These companies offer various insulin pump types, including disposable patch pumps and durable pumps with or without automated dosing algorithms.
Dexcom Incs business model focuses on developing and selling continuous glucose monitoring systems for diabetes management. Their products provide real-time glucose level tracking, enabling users to better manage their condition through data-driven insights.
Tandem Diabetes Care Inc is a medical device company that specializes in designing, manufacturing, and marketing insulin pumps. Their business model revolves around developing and selling technologically advanced insulin delivery systems to improve the quality of life for individuals with diabetes. By constantly innovating and focusing on customer needs, Tandem Diabetes Care Inc aims to capture a significant portion of the insulin pump market and establish itself as a trusted leader in the industry.
Insulet Corporation operates under a business model where they design, develop, and market innovative tubeless insulin delivery systems for people with diabetes. Their main product, the Omnipod System, is a wearable device that provides continuous insulin delivery without the need for traditional insulin pumps and tubing. This unique business model focuses on improving the quality of life for individuals with diabetes by offering a convenient and user-friendly insulin management solution.
Medtronic Plc operates a global business model centered on the development and distribution of advanced medical technologies across four key segments: Cardiac and Vascular, Minimally Invasive Therapies, Restorative Therapies, and Diabetes. The company emphasizes innovation and collaboration with healthcare providers to enhance patient outcomes and drive efficiency within healthcare systems.
Embecta Corp is a company that operates on a business-to-business (B2B) model, providing services or products to other businesses rather than individual consumers.
Sources:
Modular Medical Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Modular Medical Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
